Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03347279
Registration number
NCT03347279
Ethics application status
Date submitted
9/11/2017
Date registered
20/11/2017
Date last updated
26/11/2021
Titles & IDs
Public title
Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma
Query!
Scientific title
A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents With Severe Uncontrolled Asthma (NAVIGATOR)
Query!
Secondary ID [1]
0
0
D5180C00007
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
NAVIGATOR
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Asthma
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Asthma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - Experimental: Tezepelumab
Other interventions - Placebo
Experimental: Tezepelumab - Tezepelumab: Tezepelumab subcutaneous injection
Placebo Comparator: Placebo - Placebo: Placebo subcutaneous injection
Other interventions: Experimental: Tezepelumab
Tezepelumab subcutaneous injection
Other interventions: Placebo
Placebo subcutaneous injection
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma
Query!
Assessment method [1]
0
0
The annual exacerbation rate is based on unadjudicated exacerbations reported by the investigator in the eCRF. The analysis is based on the primary population (Full Analysis Set)
Query!
Timepoint [1]
0
0
From randomisation to Study Week 52.
Query!
Primary outcome [2]
0
0
Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma in Subjects With Baseline Eosinophils < 300 Cells/uL
Query!
Assessment method [2]
0
0
The annual exacerbation rate is based on unadjudicated exacerbations reported by the investigator in the eCRF. This analysis is based on subjects with baseline eosinophils < 300 cells/uL
Query!
Timepoint [2]
0
0
From randomisation to Study Week 52.
Query!
Secondary outcome [1]
0
0
Mean Change From Baseline at Week 52 in Pre-dose/Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1) (L) (Key Secondary Endpoint)
Query!
Assessment method [1]
0
0
Mean change from baseline in FEV1 as compared to placebo at Week 52. FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.
Query!
Timepoint [1]
0
0
From randomisation to Study Week 52
Query!
Secondary outcome [2]
0
0
Mean Change From Baseline at Week 52 in Standardized Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) Total Score (Key Secondary Endpoint)
Query!
Assessment method [2]
0
0
Mean change from baseline in AQLQ(S)+12 as compared to placebo at Week 52. The AQLQ(S)+12 is a questionnaire that measures the health-related quality of life experienced by asthma subjects. The total score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment).
Query!
Timepoint [2]
0
0
From randomisation to Study Week 52
Query!
Secondary outcome [3]
0
0
Mean Change From Baseline at Week 52 in Asthma Control Questionnaire-6(ACQ-6) (Key Secondary Endpoint)
Query!
Assessment method [3]
0
0
Change from baseline in ACQ-6 as compared to placebo at Week 52. The ACQ-6 captures asthma symptoms and short-acting ß2-agonist use via subject-report. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses.
Query!
Timepoint [3]
0
0
From randomisation to Study Week 52
Query!
Secondary outcome [4]
0
0
Mean Change From Baseline at Week 52 in Asthma Symptom Diary (Key Secondary Endpoint)
Query!
Assessment method [4]
0
0
Mean change from baseline at Week 52 in Asthma Symptom Diary. The Asthma Symptom Diary comprises of 10 items (5 items in the morning; 5 items in the evening). Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the daily diary. A daily ASD score is the mean of the 10 items. Responses for all 10 items are required to calculate the daily ASD score; otherwise, it is treated as missing. For the 7-day average asthma symptom score, scoring is done with no imputation using the mean of at least 4 of the 7 daily ASD scores as a mean weekly item score. The 7-day average ASD score ranges from 0 to 4, where 0 indicates no asthma symptoms.
Query!
Timepoint [4]
0
0
From randomisation to Study Week 52
Query!
Secondary outcome [5]
0
0
Time to First Asthma Exacerbation
Query!
Assessment method [5]
0
0
Time to first occurrence of asthma exacerbation post-randomisation, presented as number of subjects with at least one asthma exacerbation as reported by the investigator in the eCRF.
Query!
Timepoint [5]
0
0
From randomisation to Study Week 52
Query!
Secondary outcome [6]
0
0
Mean Change From Baseline at Week 52 in Clinic Fractional Exhaled Nitric Oxide (FeNO) (Ppb)
Query!
Assessment method [6]
0
0
Mean change from baseline at Study Week 52 in FeNO (ppb) measured at site
Query!
Timepoint [6]
0
0
From randomisation to Study Week 52
Query!
Secondary outcome [7]
0
0
Mean Change From Baseline in Daily Rescue Medication Use (Weekly Means) at Week 52
Query!
Assessment method [7]
0
0
Daily rescue medication use is defined as: Number of night inhaler puffs + 2 x [number of night nebulizer times] + number of daytime inhaler puffs + 2 x [number of day nebulizer times]. Weekly means are calculated using at least 4 of 7 days of daily rescue medication use.
Query!
Timepoint [7]
0
0
From randomisation to Study Week 52
Query!
Secondary outcome [8]
0
0
Mean Change From Baseline in Work Productivity Loss Due to Asthma at Week 52
Query!
Assessment method [8]
0
0
WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Work productivity loss is derived by sum of percentage of missed work due to asthma and product of percentage of actual working hours times degree of asthma affecting work productivity while working. Percentage of missed work due to asthma is calculated by number of hours missed work due to asthma divided by total number of hours missed work plus number of hours actually worked.
Query!
Timepoint [8]
0
0
From randomisation to Study Week 52
Query!
Secondary outcome [9]
0
0
Mean Change From Baseline in Class Productivity Loss Due to Asthma at Week 52
Query!
Assessment method [9]
0
0
WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Class productivity loss is derived by sum of percentage of missed class hours due to asthma and product of percentage of actual hours in class times degree of asthma affecting productivity while in class. Percentage of missed hours in class due to asthma is calculated by number of hours in class missed due to asthma divided by total number of hours in class missed plus number of hours actually in class.
Query!
Timepoint [9]
0
0
From randomisation to Study Week 52
Query!
Secondary outcome [10]
0
0
Activity Impairment at Week 52
Query!
Assessment method [10]
0
0
WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Activity impairment is the degree health affected regular activities (other than work or class) rated from 0 to 10, with 0 meaning no effect, divided by 10, and then expressed as a percentage.
Query!
Timepoint [10]
0
0
From randomisation to Study Week 52
Query!
Secondary outcome [11]
0
0
Pharmacokinetics of Tezepelumab
Query!
Assessment method [11]
0
0
Mean serum trough PK concentrations taken pre-dose at each visit
Query!
Timepoint [11]
0
0
Pre-dose samples at Baseline, Week 4, Week 12, Week 24, Week 36, Week 52, Week 64
Query!
Secondary outcome [12]
0
0
Mean Change From Baseline at Week 52 in EQ-5D-5L VAS
Query!
Assessment method [12]
0
0
Mean change from baseline at Study Week 52 in EQ-5D-5L VAS. EQ-5D-5L visual analogue scale (VAS) allows subjects to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.
Query!
Timepoint [12]
0
0
At Study Week 52
Query!
Secondary outcome [13]
0
0
Clinicians Global Impression of Change at Week 52
Query!
Assessment method [13]
0
0
CGIC (Clinical global impression of change) is an overall evaluation of response to treatment, conducted by investigator using 7-point rating scale, ranging from 1 (very much improved), to 7 (very much worse)
Query!
Timepoint [13]
0
0
From randomisation to Study Week 52
Query!
Secondary outcome [14]
0
0
Patients Global Impression of Change at Week 52
Query!
Assessment method [14]
0
0
PGIC (Patient global impression of change) is an overall evaluation of response to treatment, conducted by the patient using 7-point rating scale, ranging from 1 (very much improved), to 7 (very much worse).
Query!
Timepoint [14]
0
0
From randomisation to Study Week 52
Query!
Secondary outcome [15]
0
0
Patients Global Impression of Severity at Week 52
Query!
Assessment method [15]
0
0
PGI-S (Patient global impression of severity) is an overall evaluation of patient's perception of overall symptom severity using a 6-point rating scale, ranging from 0 = No symptoms, 1=Very mild symptoms, 2=Mild symptoms, 3=Moderate symptoms, 4=Severe symptoms, 5=Very severe symptoms
Query!
Timepoint [15]
0
0
At Study Week 52
Query!
Secondary outcome [16]
0
0
Mean Change From Baseline at Week 52 in Blood Eosinophils (Cells/uL)
Query!
Assessment method [16]
0
0
Mean change from baseline at Study Week 52 in blood eosinophils (cells/uL)
Query!
Timepoint [16]
0
0
From randomisation to Study Week 52
Query!
Secondary outcome [17]
0
0
Mean Change From Baseline at Week 52 in Total Serum IgE (IU/mL)
Query!
Assessment method [17]
0
0
Mean change from baseline at Study Week 52 in total serum IgE (IU/mL)
Query!
Timepoint [17]
0
0
From randomisation to Study Week 52
Query!
Secondary outcome [18]
0
0
Number of Participants With Asthma Specific Healthcare Utilization Over 52 Weeks
Query!
Assessment method [18]
0
0
Number of participants with asthma specific healthcare utilizations (e.g. unscheduled physician visits, unscheduled phone calls to physicians, use of other asthma medications) over 52 weeks
Query!
Timepoint [18]
0
0
From randomisation to Study Week 52
Query!
Secondary outcome [19]
0
0
Mean Change From Baseline in Home Based Morning Peak Expiratory Flow (PEF) at Week 52 (Weekly Means)
Query!
Assessment method [19]
0
0
Mean change from baseline in home based morning PEF (L/min) at Study Week 52. Home PEF testing will be performed by the subject in the morning upon awakening and in the evening at bedtime using an electronic, hand-held spirometer. Weekly means are calculated using at least 4 of the 7 days of PEF data.
Query!
Timepoint [19]
0
0
From randomisation to Study Week 52
Query!
Secondary outcome [20]
0
0
Mean Change From Baseline in Home Based Evening Peak Expiratory Flow (PEF) at Week 52 (Weekly Means)
Query!
Assessment method [20]
0
0
Mean change from baseline in home based evening PEF (L/min) at Study Week 52. Home PEF testing will be performed by the subject in the morning upon awakening and in the evening at bedtime using an electronic, hand-held spirometer. Weekly means are calculated using at least 4 of the 7 days of PEF data.
Query!
Timepoint [20]
0
0
From randomisation to Study Week 52
Query!
Secondary outcome [21]
0
0
Mean Change From Baseline in Night Time Awakenings (Weekly Means) at Week 52
Query!
Assessment method [21]
0
0
Mean change from baseline in night time awakenings due to asthma at Study Week 52. Night-time awakenings percentage defined as number of nights with awakenings due to asthma and requiring rescue medication divided by number of nights with data and multiplied by 100%. At least 4 out of 7 days of data is required to calculate a weekly mean.
Query!
Timepoint [21]
0
0
From randomisation to Study Week 52
Query!
Secondary outcome [22]
0
0
Immunogenecity of Tezepelumab
Query!
Assessment method [22]
0
0
Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at >=2 post baseline assessments (with >=16 weeks between the first and the last positive) or positive at last post baseline assessment. Transiently positive is defined as having at least one post baseline ADA positive assessment and not fulfilling the conditions of persistently positive. Treatment boosted ADA defined as baseline positive ADA that was boosted to a 4 fold or higher level following treatment. Treatment emergent ADA defined as sum of treatment induced ADA and treatment boosted ADA.
Query!
Timepoint [22]
0
0
Baseline, and from time of first dose at Week 0 to end of study at Week 64.
Query!
Secondary outcome [23]
0
0
Proportion of Subjects Who Had no Asthma Exacerbations
Query!
Assessment method [23]
0
0
The proportion of subjects who have no exacerbations is presented as the percentage of subjects with no exacerbations. This is defined as subjects who meet both the following criteria: (1) completed the 52 week treatment period and (2) did not report an exacerbation during this period.
Query!
Timepoint [23]
0
0
From randomisation to Study Week 52
Query!
Secondary outcome [24]
0
0
Annual Asthma Exacerbation Rate Resulting in Emergency Room Visit or Hospitalisation
Query!
Assessment method [24]
0
0
The annualized exacerbation rate is based on exacerbations reported by the investigator that are associated with an emergency room visit, urgent care visit, or a hospitalization (where urgent care visit was captured as an emergency room visit on the eCRF)
Query!
Timepoint [24]
0
0
From randomisation to Study Week 52
Query!
Secondary outcome [25]
0
0
Proportion of Subjects With at Least One Asthma Exacerbation Associated With Emergency Room Visit or Hospitalisation
Query!
Assessment method [25]
0
0
Proportion of subjects with at least one asthma exacerbation associated with emergency room visit or hospitalisation as recorded by the investigator in the CRF. This is presented as percentage of subjects with at least one asthma exacerbation associated with emergency room visit or hospitalisation.
Query!
Timepoint [25]
0
0
From randomisation to Study Week 52
Query!
Secondary outcome [26]
0
0
Proportion of Subjects Who Had no Asthma Exacerbations Associated With Emergency Room or Hospitalisation
Query!
Assessment method [26]
0
0
The proportion of subjects with no exacerbations is presented as percentage of subjects who meet both the following criteria: (1) completed the 52 week treatment period and (2) did not report an exacerbation associated with emergency room or hospitalisation during this period.
Query!
Timepoint [26]
0
0
From randomisation to Study Week 52
Query!
Eligibility
Key inclusion criteria
- Age. 12-80
- Documented physician-diagnosed asthma for at least 12 months
- Subjects who have received a physician-prescribed asthma controller medication with
medium or high dose ICS for at least 12 months.
- Documented treatment with a total daily dose of either medium or high dose ICS (= 500
µg fluticasone propionate dry powder formulation equivalent total daily dose) for at
least 3 months.
- At least one additional maintenance asthma controller medication is required according
to standard practice of care and must be documented for at least 3 months.
- Morning pre-BD FEV1 <80% predicted normal (<90% for subjects 12-17 yrs)
- Evidence of asthma as documented by either: Documented historical reversibility of
FEV1 =12% and =200 mL in the previous 12 months OR Post-BD (albuterol/salbutamol)
reversibility of FEV1 =12% and =200 mL during screening.
- Documented history of at least 2 asthma exacerbation events within 12 months.
- ACQ-6 score =1.5 at screening and on day of randomization
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Pulmonary disease other than asthma.
- History of cancer.
- History of a clinically significant infection.
- Current smokers or subjects with smoking history =10 pack-years and subjects using
vaping products, including electronic cigarettes.
- History of chronic alcohol or drug abuse within 12 months.
- Hepatitis B, C or HIV.
- Pregnant or breastfeeding.
- History of anaphylaxis following any biologic therapy.
- Subject randomized in the current study or previous tezepelumab studies.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
23/11/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
12/11/2020
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1061
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Research Site - Campbelltown
Query!
Recruitment hospital [2]
0
0
Research Site - Kent Town
Query!
Recruitment hospital [3]
0
0
Research Site - Melbourne
Query!
Recruitment hospital [4]
0
0
Research Site - Nedlands
Query!
Recruitment hospital [5]
0
0
Research Site - New Lambton
Query!
Recruitment hospital [6]
0
0
Research Site - Spearwood
Query!
Recruitment hospital [7]
0
0
Research Site - Westmead
Query!
Recruitment hospital [8]
0
0
Research Site - Woolloongabba
Query!
Recruitment postcode(s) [1]
0
0
2560 - Campbelltown
Query!
Recruitment postcode(s) [2]
0
0
5067 - Kent Town
Query!
Recruitment postcode(s) [3]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [4]
0
0
6009 - Nedlands
Query!
Recruitment postcode(s) [5]
0
0
2310 - New Lambton
Query!
Recruitment postcode(s) [6]
0
0
6163 - Spearwood
Query!
Recruitment postcode(s) [7]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [8]
0
0
4102 - Woolloongabba
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Idaho
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Indiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Kentucky
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Louisiana
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Maryland
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Massachusetts
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Michigan
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Missouri
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Nebraska
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Nevada
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New Jersey
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
New York
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
North Carolina
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Ohio
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Oklahoma
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Oregon
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Pennsylvania
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Rhode Island
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
South Carolina
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Texas
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Virginia
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Wisconsin
Query!
Country [30]
0
0
Argentina
Query!
State/province [30]
0
0
Buenos Aires
Query!
Country [31]
0
0
Argentina
Query!
State/province [31]
0
0
Caba
Query!
Country [32]
0
0
Argentina
Query!
State/province [32]
0
0
Ciudad de Buenos Aires
Query!
Country [33]
0
0
Argentina
Query!
State/province [33]
0
0
Córdoba
Query!
Country [34]
0
0
Argentina
Query!
State/province [34]
0
0
Mendoza
Query!
Country [35]
0
0
Argentina
Query!
State/province [35]
0
0
Nueve de julio
Query!
Country [36]
0
0
Argentina
Query!
State/province [36]
0
0
Quilmes
Query!
Country [37]
0
0
Austria
Query!
State/province [37]
0
0
Klagenfurt
Query!
Country [38]
0
0
Austria
Query!
State/province [38]
0
0
Linz
Query!
Country [39]
0
0
Austria
Query!
State/province [39]
0
0
Salzburg
Query!
Country [40]
0
0
Austria
Query!
State/province [40]
0
0
Wien
Query!
Country [41]
0
0
Brazil
Query!
State/province [41]
0
0
Blumenau
Query!
Country [42]
0
0
Brazil
Query!
State/province [42]
0
0
Botucatu
Query!
Country [43]
0
0
Brazil
Query!
State/province [43]
0
0
Curitiba
Query!
Country [44]
0
0
Brazil
Query!
State/province [44]
0
0
Porto Alegre
Query!
Country [45]
0
0
Brazil
Query!
State/province [45]
0
0
Recife
Query!
Country [46]
0
0
Brazil
Query!
State/province [46]
0
0
Salvador
Query!
Country [47]
0
0
Brazil
Query!
State/province [47]
0
0
Santo Andre
Query!
Country [48]
0
0
Brazil
Query!
State/province [48]
0
0
Sao Bernardo do Campo
Query!
Country [49]
0
0
Brazil
Query!
State/province [49]
0
0
Sorocaba
Query!
Country [50]
0
0
Brazil
Query!
State/province [50]
0
0
Vitória
Query!
Country [51]
0
0
Canada
Query!
State/province [51]
0
0
Alberta
Query!
Country [52]
0
0
Canada
Query!
State/province [52]
0
0
British Columbia
Query!
Country [53]
0
0
Canada
Query!
State/province [53]
0
0
Ontario
Query!
Country [54]
0
0
Canada
Query!
State/province [54]
0
0
Quebec
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Brest Cedex
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
GRENOBLE Cedex 9
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Le Kremlin Bicêtre
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Lille Cedex
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Lyon Cedex 04
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
MARSEILLE Cedex 20
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Montpellier Cedex 5
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Nantes Cedex 1
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
PARIS Cedex 12
Query!
Country [64]
0
0
France
Query!
State/province [64]
0
0
Paris Cedex 18
Query!
Country [65]
0
0
France
Query!
State/province [65]
0
0
Paris
Query!
Country [66]
0
0
France
Query!
State/province [66]
0
0
Pessac
Query!
Country [67]
0
0
France
Query!
State/province [67]
0
0
Strasbourg Cedex
Query!
Country [68]
0
0
France
Query!
State/province [68]
0
0
Toulouse CEDEX 09
Query!
Country [69]
0
0
Germany
Query!
State/province [69]
0
0
Bamberg
Query!
Country [70]
0
0
Germany
Query!
State/province [70]
0
0
Berlin
Query!
Country [71]
0
0
Germany
Query!
State/province [71]
0
0
Frankfurt am Main
Query!
Country [72]
0
0
Germany
Query!
State/province [72]
0
0
Frankfurt
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Hamburg
Query!
Country [74]
0
0
Germany
Query!
State/province [74]
0
0
Hannover
Query!
Country [75]
0
0
Germany
Query!
State/province [75]
0
0
Landsberg
Query!
Country [76]
0
0
Germany
Query!
State/province [76]
0
0
Leipzig
Query!
Country [77]
0
0
Germany
Query!
State/province [77]
0
0
Lübeck
Query!
Country [78]
0
0
Germany
Query!
State/province [78]
0
0
Mainz
Query!
Country [79]
0
0
Israel
Query!
State/province [79]
0
0
Ashkelon
Query!
Country [80]
0
0
Israel
Query!
State/province [80]
0
0
Haifa
Query!
Country [81]
0
0
Israel
Query!
State/province [81]
0
0
Jerusalem
Query!
Country [82]
0
0
Israel
Query!
State/province [82]
0
0
Kfar Saba
Query!
Country [83]
0
0
Israel
Query!
State/province [83]
0
0
Rehovot
Query!
Country [84]
0
0
Japan
Query!
State/province [84]
0
0
Bunkyo-ku
Query!
Country [85]
0
0
Japan
Query!
State/province [85]
0
0
Chuo-ku
Query!
Country [86]
0
0
Japan
Query!
State/province [86]
0
0
Edogawa-ku
Query!
Country [87]
0
0
Japan
Query!
State/province [87]
0
0
Fujieda-shi
Query!
Country [88]
0
0
Japan
Query!
State/province [88]
0
0
Fukuoka-shi
Query!
Country [89]
0
0
Japan
Query!
State/province [89]
0
0
Habikino-shi
Query!
Country [90]
0
0
Japan
Query!
State/province [90]
0
0
Hamamatsu-shi
Query!
Country [91]
0
0
Japan
Query!
State/province [91]
0
0
Higashiibaraki-gun
Query!
Country [92]
0
0
Japan
Query!
State/province [92]
0
0
Himeji-shi
Query!
Country [93]
0
0
Japan
Query!
State/province [93]
0
0
Hitachi-shi
Query!
Country [94]
0
0
Japan
Query!
State/province [94]
0
0
Itabashi-ku
Query!
Country [95]
0
0
Japan
Query!
State/province [95]
0
0
Kagoshima-shi
Query!
Country [96]
0
0
Japan
Query!
State/province [96]
0
0
Kanazawa-shi
Query!
Country [97]
0
0
Japan
Query!
State/province [97]
0
0
Kasuga-shi
Query!
Country [98]
0
0
Japan
Query!
State/province [98]
0
0
Kishiwada-shi
Query!
Country [99]
0
0
Japan
Query!
State/province [99]
0
0
Kitakyusyu
Query!
Country [100]
0
0
Japan
Query!
State/province [100]
0
0
Koga-shi
Query!
Country [101]
0
0
Japan
Query!
State/province [101]
0
0
Matsusaka-shi
Query!
Country [102]
0
0
Japan
Query!
State/province [102]
0
0
Meguro-ku
Query!
Country [103]
0
0
Japan
Query!
State/province [103]
0
0
Minato-ku
Query!
Country [104]
0
0
Japan
Query!
State/province [104]
0
0
Mizunami-shi
Query!
Country [105]
0
0
Japan
Query!
State/province [105]
0
0
Nagaoka-shi
Query!
Country [106]
0
0
Japan
Query!
State/province [106]
0
0
Niigata-shi
Query!
Country [107]
0
0
Japan
Query!
State/province [107]
0
0
Ogaki-shi
Query!
Country [108]
0
0
Japan
Query!
State/province [108]
0
0
Ohota-ku
Query!
Country [109]
0
0
Japan
Query!
State/province [109]
0
0
Omuta-shi
Query!
Country [110]
0
0
Japan
Query!
State/province [110]
0
0
Sagamihara-shi
Query!
Country [111]
0
0
Japan
Query!
State/province [111]
0
0
Sapporo-shi
Query!
Country [112]
0
0
Japan
Query!
State/province [112]
0
0
Setagaya-ku
Query!
Country [113]
0
0
Japan
Query!
State/province [113]
0
0
Shibuya-ku
Query!
Country [114]
0
0
Japan
Query!
State/province [114]
0
0
Shinagawa-ku
Query!
Country [115]
0
0
Japan
Query!
State/province [115]
0
0
Shinjuku-ku
Query!
Country [116]
0
0
Japan
Query!
State/province [116]
0
0
Sumida-ku
Query!
Country [117]
0
0
Japan
Query!
State/province [117]
0
0
Takamatsu-shi
Query!
Country [118]
0
0
Japan
Query!
State/province [118]
0
0
Toshima-ku
Query!
Country [119]
0
0
Japan
Query!
State/province [119]
0
0
Ube
Query!
Country [120]
0
0
Japan
Query!
State/province [120]
0
0
Yokkaichi-shi
Query!
Country [121]
0
0
Japan
Query!
State/province [121]
0
0
Yokohama-shi
Query!
Country [122]
0
0
Japan
Query!
State/province [122]
0
0
Yoshida-gun
Query!
Country [123]
0
0
Korea, Republic of
Query!
State/province [123]
0
0
Bucheon-si
Query!
Country [124]
0
0
Korea, Republic of
Query!
State/province [124]
0
0
Cheongju-si
Query!
Country [125]
0
0
Korea, Republic of
Query!
State/province [125]
0
0
Daegu
Query!
Country [126]
0
0
Korea, Republic of
Query!
State/province [126]
0
0
Jeju-si
Query!
Country [127]
0
0
Korea, Republic of
Query!
State/province [127]
0
0
Jeonju-si
Query!
Country [128]
0
0
Korea, Republic of
Query!
State/province [128]
0
0
Seongnam-si
Query!
Country [129]
0
0
Korea, Republic of
Query!
State/province [129]
0
0
Seoul
Query!
Country [130]
0
0
Korea, Republic of
Query!
State/province [130]
0
0
Suwon-si
Query!
Country [131]
0
0
Russian Federation
Query!
State/province [131]
0
0
Izhevsk
Query!
Country [132]
0
0
Russian Federation
Query!
State/province [132]
0
0
Moscow
Query!
Country [133]
0
0
Russian Federation
Query!
State/province [133]
0
0
St-Petersburg
Query!
Country [134]
0
0
Saudi Arabia
Query!
State/province [134]
0
0
Jeddah
Query!
Country [135]
0
0
South Africa
Query!
State/province [135]
0
0
Bellville
Query!
Country [136]
0
0
South Africa
Query!
State/province [136]
0
0
Boksburg North
Query!
Country [137]
0
0
South Africa
Query!
State/province [137]
0
0
Cape Town
Query!
Country [138]
0
0
South Africa
Query!
State/province [138]
0
0
Durban
Query!
Country [139]
0
0
South Africa
Query!
State/province [139]
0
0
Johannesburg
Query!
Country [140]
0
0
South Africa
Query!
State/province [140]
0
0
Lenasia Ext8
Query!
Country [141]
0
0
South Africa
Query!
State/province [141]
0
0
Middelburg
Query!
Country [142]
0
0
South Africa
Query!
State/province [142]
0
0
Mowbray
Query!
Country [143]
0
0
South Africa
Query!
State/province [143]
0
0
Parow
Query!
Country [144]
0
0
South Africa
Query!
State/province [144]
0
0
Pretoria
Query!
Country [145]
0
0
South Africa
Query!
State/province [145]
0
0
Umkomaas
Query!
Country [146]
0
0
South Africa
Query!
State/province [146]
0
0
Witbank
Query!
Country [147]
0
0
Taiwan
Query!
State/province [147]
0
0
Hsinchu
Query!
Country [148]
0
0
Taiwan
Query!
State/province [148]
0
0
Kaohsiung City
Query!
Country [149]
0
0
Taiwan
Query!
State/province [149]
0
0
Kaohsiung Hsien
Query!
Country [150]
0
0
Taiwan
Query!
State/province [150]
0
0
Kaohsiung
Query!
Country [151]
0
0
Taiwan
Query!
State/province [151]
0
0
Taichung
Query!
Country [152]
0
0
Taiwan
Query!
State/province [152]
0
0
Tainan City
Query!
Country [153]
0
0
Taiwan
Query!
State/province [153]
0
0
Taipei
Query!
Country [154]
0
0
Taiwan
Query!
State/province [154]
0
0
Yilan
Query!
Country [155]
0
0
Ukraine
Query!
State/province [155]
0
0
Ivano-Frankivsk
Query!
Country [156]
0
0
Ukraine
Query!
State/province [156]
0
0
Kharkiv Region
Query!
Country [157]
0
0
United Kingdom
Query!
State/province [157]
0
0
London
Query!
Country [158]
0
0
Vietnam
Query!
State/province [158]
0
0
Ha Noi
Query!
Country [159]
0
0
Vietnam
Query!
State/province [159]
0
0
Hanoi
Query!
Country [160]
0
0
Vietnam
Query!
State/province [160]
0
0
Ho Chi Minh
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
AstraZeneca
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Amgen
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to
Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe
Uncontrolled Asthma
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03347279
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Andrew Menzies-Gow, MD
Query!
Address
0
0
Royal Brompton Hospital, United Kingdom
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03347279
Download to PDF